214 related articles for article (PubMed ID: 28389164)
1. Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes.
Kanayama S; Okamoto K; Ikeda F; Ishii R; Matsumoto T; Hayashi N; Gotoh N
J Infect Chemother; 2017 Jun; 23(6):374-380. PubMed ID: 28389164
[TBL] [Abstract][Full Text] [Related]
2. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
[TBL] [Abstract][Full Text] [Related]
3. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
J Antimicrob Chemother; 2015 Jan; 70(1):57-61. PubMed ID: 25261416
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris.
Nakajima A; Ikeda F; Kanayama S; Okamoto K; Matsumoto T; Ishii R; Fujikawa A; Takei K; Kawashima M
J Med Microbiol; 2016 Aug; 65(8):745-750. PubMed ID: 27305898
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activity of benzoyl peroxide against Propionibacterium acnes assessed by a novel susceptibility testing method.
Okamoto K; Ikeda F; Kanayama S; Nakajima A; Matsumoto T; Ishii R; Umehara M; Gotoh N; Hayashi N; Iyoda T; Matsuzaki K; Matsumoto S; Kawashima M
J Infect Chemother; 2016 Jun; 22(6):426-9. PubMed ID: 26806150
[TBL] [Abstract][Full Text] [Related]
6. Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.
Tato M; López Y; Morosini MI; Moreno-Bofarull A; Garcia-Alonso F; Gargallo-Viola D; Vila J; Cantón R
Diagn Microbiol Infect Dis; 2014 Mar; 78(3):263-7. PubMed ID: 24321353
[TBL] [Abstract][Full Text] [Related]
7. [Fundamental studies on antibacterial activity of clindamycin against Propionibacterium acnes].
Komagata Y; Komiyama K; Nomura S
Jpn J Antibiot; 1998 Feb; 51(2):130-6. PubMed ID: 9575439
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris.
Kurokawa I; Nishijima S; Kawabata S
Eur J Dermatol; 1999; 9(1):25-8. PubMed ID: 9920982
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.
Ross JI; Snelling AM; Eady EA; Cove JH; Cunliffe WJ; Leyden JJ; Collignon P; Dréno B; Reynaud A; Fluhr J; Oshima S
Br J Dermatol; 2001 Feb; 144(2):339-46. PubMed ID: 11251569
[TBL] [Abstract][Full Text] [Related]
10. Microbiological profile of ozenoxacin.
Morrissey I; Cantón R; Vila J; Gargallo-Viola D; Zsolt I; Garcia-Castillo M; López Y
Future Microbiol; 2019 Jun; 14():773-787. PubMed ID: 31132895
[No Abstract] [Full Text] [Related]
11. Anti-inflammatory effects of ozenoxacin, a topical quinolone antimicrobial agent.
Tabara K; Tamura R; Nakamura A; Mori S; Kitano T; Fujikawa K; Fujikawa M; Okamoto K; Kanayama S; Uratsuji H; Ikeda F; Matsumoto T
J Antibiot (Tokyo); 2020 Apr; 73(4):247-254. PubMed ID: 31974519
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections.
Mory F; Fougnot S; Rabaud C; Schuhmacher H; Lozniewski A
J Antimicrob Chemother; 2005 Feb; 55(2):265-8. PubMed ID: 15590714
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea.
Song M; Seo SH; Ko HC; Oh CK; Kwon KS; Chang CL; Kim MB
J Dermatol; 2011 Jul; 38(7):667-73. PubMed ID: 21352337
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of lipase activity in antibiotic-resistant propionibacterium acnes strains.
Gloor M; Wasik B; Becker A; Höffler U
Dermatology; 2002; 205(3):260-4. PubMed ID: 12399674
[TBL] [Abstract][Full Text] [Related]
15. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions.
Nishijima S; Kurokawa I; Katoh N; Watanabe K
J Dermatol; 2000 May; 27(5):318-23. PubMed ID: 10875198
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
Yamakawa T; Mitsuyama J; Hayashi K
J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
Canton R; Morrissey I; Vila J; Tato M; García-Castillo M; López Y; Gargallo-Viola D; Zsolt I
Future Microbiol; 2018 May; 13():3-19. PubMed ID: 29745242
[TBL] [Abstract][Full Text] [Related]
18. Propionibacterium acnes Has Low Susceptibility to Chlorhexidine Digluconate.
Nakase K; Fukushima H; Yukawa T; Nakaminami H; Fujii T; Noguchi N
Surg Infect (Larchmt); 2018 Apr; 19(3):298-302. PubMed ID: 29447075
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of strains of Propionibacterium acnes isolated from inflammatory acne.
Gübelin W; Martínez MA; Molina MT; Zapata S; Valenzuela ME
Rev Latinoam Microbiol; 2006; 48(1):14-6. PubMed ID: 17357569
[TBL] [Abstract][Full Text] [Related]
20. Determination of the Mutant Prevention Concentration and the Mutant Selection Window of Topical Antimicrobial Agents against Propionibacterium acnes.
Nakase K; Nakaminami H; Toda Y; Noguchi N
Chemotherapy; 2017; 62(2):94-99. PubMed ID: 27764829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
